Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer
Xuenong Ouyang,Meiqi Shi,Fangwei Jie,Yuxian Bai,Peng Shen,Zhuang Yu,Xiuwen Wang,Cheng Huang,Min Tao,Zhehai Wang,Conghua Xie,Qi Wu,Yongqian Shu,Baohui Han,Fengchun Zhang,Yiping Zhang,Chunhong Hu,Xitao Ma,Yongjie Liang,Anlan Wang,Bing Lu,Yi Shi,Jinfei Chen,Zhixiang Zhuang,Jiejun Wang,Jianjin Huang,Changhui Wang,Chunxue Bai,Xin Zhou,Qiang Li,Feng Chen,Hao Yu,Jifeng Feng
DOI: https://doi.org/10.1007/s10637-017-0536-y
2017-01-01
Investigational New Drugs
Abstract:Summary Background Dulanermin is a recombinant soluble human Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) that activates apoptotic pathways by binding to proapoptotic death receptor (DR) 4 and DR5. The purpose of this study was to evaluate the efficacy and safety of dulanermin combined with vinorelbine and cisplatin (NP) as the first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC). Experimental design Patients were randomly assigned to receive NP chemotherapy (vinorelbine 25 mg/m 2 on days 1 and 8 and cisplatin 30 mg/m 2 on days 2 to 4) for up to six cycles plus dulanermin (75 μg/kg on days 1 to 14) or placebo every three weeks until disease progression, intolerable toxicity, or withdrawal of consent. The primary end point was progression-free survival (PFS), and the secondary end points included objective response rate (ORR), overall survival (OS), and safety evaluation. Results Between October 2009 and June 2012, 452 untreated patients with stage IIIB to IV NSCLC were randomly assigned to receive dulanermin plus NP ( n = 342) and placebo plus NP ( n = 110). Median PFS was 6.4 months in the dulanermin arm versus 3.5 months in the placebo arm (hazard ratio (HR), 0.4034; 95% CI, 0.3181 to 0.5117, p < 0.0001). ORR was 46.78% in the dulanermin arm versus 30.00% in the placebo arm ( p = 0.0019). Median OS was 14.6 months in the dulanermin arm versus 13.9 months in the placebo arm (HR, 0.94; 95% CI, 0.74 to 1.21, p = 0.64). The most common grade ≥ 3 adverse events (AEs) were oligochromemia, leukopenia, neutropenia, and oligocythemia. Overall incidence of AEs, grade ≥ 3 AEs, and serious AEs were similar across the two arms. Conclusion Addition of dulanermin to the NP regimen significantly improved PFS and ORR. However, our results showed that the combination of dulanermin with chemotherapy had a synergic activity and favorable toxic profile in the treatment of patients with advanced NSCLC.